Raily Aesthetic Medicine International Holdings (HKG:2135) expects a loss attributable to owners of 59 million yuan for 2024, compared with 32 million yuan in the prior year, according to a Monday filing with the Hong Kong bourse.
The company attributed the projected wider loss to impairments provisions in the business, increased share option expenses, and higher investment in research and development.
The company is expected to publish final results by the end of March.
The aesthetic medical services company stocks were down by 2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。